TY - JOUR
T1 - Positron emission tomography in thyroid cancer management
AU - Larson, Steven M.
AU - Robbins, Richard
N1 - Funding Information:
From the Department of Radiology, Chief Nuclear Medicine Service; the Department of Radiology, Laurent and Alberta Gershel PET Center, Department of Radiology; and the Chief Medical Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Supported by The Laurent and Alberta Gerschel Foundation. Address reprint requests to Steven M. Larson, MD, Nuclear Medicine Service SC212 1275 York Avenue, New York, NY 10021. Copyright 2002, Elsevier Science (USA). All rights reserved. 0037-198X/02/3702-0008535.00/0 doi: l O.1 053/sroe.2002.34 210
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2002/4
Y1 - 2002/4
N2 - Selected patients with thyroid cancer can benefit from the use of PET imaging with FDG or with I-124. The PET scan impacts on management by providing (1) more accurate information about staging of patients in terms of extent of tumor for better treatment planning, especially in patients who do not concentration radioactive I-131; (2) the relationship of tumor involvement to vital structures, especially in the neck and central nervous system; and (3) prognostic information (an SUV > 10 and extensive PET + disease connotes a poor prognosis in advanced patients). In the occasional patient, surgically respectable disease has been identified on PET with the result that the patient has been rendered no evident disease with treatment. PET has also been used in the follow-up of patients who have been treated for thyroid cancer, to assess response. PET may also be useful for lesion specific dosimetry, with I-124. The combination of PET and CT in the same gantry facilitates localization of thyroid cancer PET scan abnormalities in relationship to critical organs and structures.
AB - Selected patients with thyroid cancer can benefit from the use of PET imaging with FDG or with I-124. The PET scan impacts on management by providing (1) more accurate information about staging of patients in terms of extent of tumor for better treatment planning, especially in patients who do not concentration radioactive I-131; (2) the relationship of tumor involvement to vital structures, especially in the neck and central nervous system; and (3) prognostic information (an SUV > 10 and extensive PET + disease connotes a poor prognosis in advanced patients). In the occasional patient, surgically respectable disease has been identified on PET with the result that the patient has been rendered no evident disease with treatment. PET has also been used in the follow-up of patients who have been treated for thyroid cancer, to assess response. PET may also be useful for lesion specific dosimetry, with I-124. The combination of PET and CT in the same gantry facilitates localization of thyroid cancer PET scan abnormalities in relationship to critical organs and structures.
UR - http://www.scopus.com/inward/record.url?scp=0035996005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035996005&partnerID=8YFLogxK
U2 - 10.1016/S0037-198X(02)80035-9
DO - 10.1016/S0037-198X(02)80035-9
M3 - Article
C2 - 12134369
AN - SCOPUS:0035996005
VL - 37
SP - 169
EP - 174
JO - Seminars in Roentgenology
JF - Seminars in Roentgenology
SN - 0037-198X
IS - 2
ER -